Cargando…
Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer
Although cisplatin is one of the most common antineoplastic drug, its successful utilisation in cancer treatment is limited by the drug resistance. Multiple attempts have been made to find potential cisplatin chemosensitisers which would overcome cancer cells resistance thus improving antineoplastic...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960624/ https://www.ncbi.nlm.nih.gov/pubmed/33159673 http://dx.doi.org/10.1007/s10637-020-01032-y |
_version_ | 1783665090973663232 |
---|---|
author | Gąsiorkiewicz, Bartosz Mateusz Koczurkiewicz-Adamczyk, Paulina Piska, Kamil Pękala, Elżbieta |
author_facet | Gąsiorkiewicz, Bartosz Mateusz Koczurkiewicz-Adamczyk, Paulina Piska, Kamil Pękala, Elżbieta |
author_sort | Gąsiorkiewicz, Bartosz Mateusz |
collection | PubMed |
description | Although cisplatin is one of the most common antineoplastic drug, its successful utilisation in cancer treatment is limited by the drug resistance. Multiple attempts have been made to find potential cisplatin chemosensitisers which would overcome cancer cells resistance thus improving antineoplastic efficacy. Autophagy modulation has become an important area of interest regarding the aforementioned topic. Autophagy is a highly conservative cellular self-digestive process implicated in response to multiple environmental stressors. The high basal level of autophagy is a common phenomenon in cisplatin-resistant cancer cells which is thought to grant survival benefit. However current evidence supports the role of autophagy in either promoting or limiting carcinogenesis depending on the context. This encourages the search of substances modulating the process to alleviate cisplatin resistance. Such a strategy encompasses not only simple autophagy inhibition but also harnessing the process to induce autophagy-dependent cell death. In this paper, we briefly describe the mechanism of cisplatin resistance with a special emphasis on autophagy and we give an extensive literature review of potential substances with cisplatin chemosensitising properties related to autophagy modulation. |
format | Online Article Text |
id | pubmed-7960624 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-79606242021-04-01 Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer Gąsiorkiewicz, Bartosz Mateusz Koczurkiewicz-Adamczyk, Paulina Piska, Kamil Pękala, Elżbieta Invest New Drugs Review Although cisplatin is one of the most common antineoplastic drug, its successful utilisation in cancer treatment is limited by the drug resistance. Multiple attempts have been made to find potential cisplatin chemosensitisers which would overcome cancer cells resistance thus improving antineoplastic efficacy. Autophagy modulation has become an important area of interest regarding the aforementioned topic. Autophagy is a highly conservative cellular self-digestive process implicated in response to multiple environmental stressors. The high basal level of autophagy is a common phenomenon in cisplatin-resistant cancer cells which is thought to grant survival benefit. However current evidence supports the role of autophagy in either promoting or limiting carcinogenesis depending on the context. This encourages the search of substances modulating the process to alleviate cisplatin resistance. Such a strategy encompasses not only simple autophagy inhibition but also harnessing the process to induce autophagy-dependent cell death. In this paper, we briefly describe the mechanism of cisplatin resistance with a special emphasis on autophagy and we give an extensive literature review of potential substances with cisplatin chemosensitising properties related to autophagy modulation. Springer US 2020-11-07 2021 /pmc/articles/PMC7960624/ /pubmed/33159673 http://dx.doi.org/10.1007/s10637-020-01032-y Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Gąsiorkiewicz, Bartosz Mateusz Koczurkiewicz-Adamczyk, Paulina Piska, Kamil Pękala, Elżbieta Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer |
title | Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer |
title_full | Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer |
title_fullStr | Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer |
title_full_unstemmed | Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer |
title_short | Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer |
title_sort | autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960624/ https://www.ncbi.nlm.nih.gov/pubmed/33159673 http://dx.doi.org/10.1007/s10637-020-01032-y |
work_keys_str_mv | AT gasiorkiewiczbartoszmateusz autophagymodulatingagentsaschemosensitizersforcisplatintherapyincancer AT koczurkiewiczadamczykpaulina autophagymodulatingagentsaschemosensitizersforcisplatintherapyincancer AT piskakamil autophagymodulatingagentsaschemosensitizersforcisplatintherapyincancer AT pekalaelzbieta autophagymodulatingagentsaschemosensitizersforcisplatintherapyincancer |